David Hutton

At this year's American Academy of Ophthalmology meeting in San Francisco, California, Penny Asbell, MD, FACS, presented results from the ARMOR Study

At this year's American Academy of Ophthalmology meeting, the Ophthalmology Times team spoke with Megan Baldwin, MD, founder of Opthea Limited, about the company's ShORe and COAST clinical trials

At AAO 2023, Rich Small, CEO of Neurotech, spoke with our team about the company's development of encapsulated cell therapy, NT-501

At the 2023 AAO meeting, Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

At this year's American Academy of Ophthalmology meeting, Anthony Wallace, BS, MBA, vice president and general manager of the surgical business at Bausch + Lomb North America, spoke with us about three exciting new launches

Ben Bergo, CEO of Visus Therapeutics, spoke with Ophthalmology Times about the BRIO-I study on presbyopia

Researchers from Anglia Ruskin University and the University of Oxford conducted a study that reveals knowledge gaps for conditions that affect 18-64-year-olds in the UK

In a conversation with Ophthalmology Times, Mary Elizabeth Hartnett, MD, FACS, discussed her AAO presentation, focusing on the impact of blindness and vision loss on women in the United States

Esen K. Akpek, MD, discussed her presentation at this year's American Academy of Ophthalmology meeting, covering recent advancements in artificial corneas

Kerrie Brady, president and chief executive officer of OcuTerra Therapeutics, shares progress in their Phase 2 DR:EAM Diabetic Retinopathy study, with promising results expected in Q1 2024 for their OTT166 eye drop treatment.

Surgeons can save space and optimise workflow efficiency in the operating room

The collection at the Truhlsen-Marmor Museum of the Eye includes more than 38,000 objects, including rare books, instruments and immersive educational materials.

According to Genentech, RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular oedema

The patent is also being prosecuted in the European Union and around the globe

Mutations in the EMC1 gene appear to be associated with familial exudative vitreoretinopathy (FEVR), a severe ocular condition.

Our team spoke to David Almeida, MD, PhD, MBA about his EURETINA presentation titled, The Real-World Efficacy and Safety of Faricimab in Neovascular AMD: The TRUCKEE Study.

Our team spoke to Varun Chaudhary, MD, about his EURETINA presentation, titled "Systematic Review and Metanalysis in Macular Hole RCTs – Posturing after Macular Hole Surgery"

Ocuphire Pharma and Viatris developed the drug together for the reversal of pharmacologically-induced mydriasis (RM) produced by adrenergic agonist or parasympatholytic agents

Research from Orbis International analyses the overall wellbeing of children with common childhood vision problems

MERCURY-3 trial data show latanoprost/netarsudil fixed-dose combination (Roclanda) demonstrated comparable IOP lowering efficacy to bimatoprost/timolol combination, in patients with primary open-angle glaucoma or ocular hypertension.

According to Bausch + Lomb, MIEBO (perfluorohexyloctane ophthalmic solution), commercialised as EvoTears in Europe, is the first prescription eye drop that targets tear evaporation.

The company has 9 presentations at the annual congress of the European Society of Cataract and Refractive Surgeons being held in Vienna. AVG also is a sponsor of the International Society of Presbyopia.

According to the company, the deal expands its European footprint into Spain and Portugal.

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Diana Do, MD, Shawn Kavoussi, MD, and Durga Borkar, MD, MMCi had to say!

At the 2023 American Society of Retina Specialists meeting in Seattle, Washington, we asked some of the presenters, "What research here do you find exciting or interesting?" Here's what Ursula Schmidt-Erfurth, MD, Veena Raiji, MD, and Dante Pieramici, MD had to say!

"What research at the 2023 ASRS meeting do you find exciting or interesting?" Here's what Aaron Lee, MD, Megan Baldwin, PhD, and Carl Danzig, MD had to say!

Maria H. Berrocal, MD, spoke with our team about her presentation at the Women in Ophthalmology Summer Symposium in Marco Island, Florida.

According to the company, it is working with the FDA to address the agency’s issues.

Eva Kim, MD, spoke with our team to share insights from her presentation on ICL versus CLE at the Women in Ophthalmology Summer Symposium 2023 in Marco Island, Florida.

ATSN-201 leverages novel spreading capsid to overcome challenges associated with intravitreally delivered AAVs in the treatment of XLRS.